{
    "clinical_study": {
        "@rank": "46959", 
        "arm_group": {
            "arm_group_label": "Adalimumab 80 mg", 
            "arm_group_type": "Experimental", 
            "description": "Subjects will be given subcutaneous injections of open-label adalimumab 80 mg eow from Week 0 to Week 50."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the efficacy, safety and pharmacokinetics after\n      dose escalation in Japanese subjects with Crohn's Disease."
        }, 
        "brief_title": "A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease", 
        "completion_date": {
            "#text": "July 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Crohn's Disease", 
        "condition_browse": {
            "mesh_term": "Crohn Disease"
        }, 
        "detailed_description": {
            "textblock": "Subjects who are confirmed to meet all of the inclusion criteria and none of the exclusion\n      criteria during screening period (=<21 days) will be given subcutaneous injections of\n      open-label adalimumab 80 mg eow from Week 0 to Week 50. If a subject has an inadequate\n      response at or after Week 8, the subject may be withdrawn from the study. Self-injection of\n      study drug is permitted for the subjects who are willing to perform self-injection, if the\n      investigator decided as appropriate. Disease activity will be evaluated by Crohn's disease\n      activity index (CDAI) at Screening, Week 0 and every 4 weeks until Week 52.  Follow-up will\n      be performed at 70 days after the last dose of study drug by visit or telephone etc."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject >=15 years of age at the time of informed consent.\n\n          -  Subject with Crohn's disease who received induction treatment of commercially\n             available Humira\u00ae (160 mg initially and 80 mg at 2 weeks after initial dose),\n             achieved response after initial dose, and then lost response during maintenance\n             treatment with Humira\u00ae.\n\n          -  Subject with elevated CRP at Screening.\n\n          -  If female, subject is either not of childbearing potential, defined as postmenopausal\n             for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral\n             oophorectomy and/or hysterectomy) or is of childbearing potential and is practicing\n             an approved method of birth control throughout the study and for 150 days after the\n             last dose of study drug.\n\n          -  Subject has a negative Tuberculosis (TB) Screening Assessment.  If the subject has\n             evidence of a latent TB infection; the subject must initiate and complete a minimum\n             of 21 days of an ongoing TB prophylaxis (in such case, screening period can be\n             prolonged until 21 days past after initiation of prophylaxis and study drug is\n             administered) or have documented completion of a full course of TB prophylaxis, prior\n             to Week 0.\n\n        Exclusion Criteria:\n\n          -  Subject with suspicion of colitis other than Crohn's disease.\n\n          -  Subject with an ostomy or ileoanal pouch. (Subjects with a previous ileo-rectal\n             anastomosis are not excluded).\n\n          -  Subject with abscess or suspicion of abscess, or subject with infection(s)."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "15 Years"
        }, 
        "enrollment": {
            "#text": "28", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01958827", 
            "org_study_id": "M13-687"
        }, 
        "intervention": {
            "arm_group_label": "Adalimumab 80 mg", 
            "description": "Subjects will be given subcutaneous injections of open-label adalimumab 80 mg eow from Week 0 to Week 50.", 
            "intervention_name": "Adalimumab", 
            "intervention_type": "Biological", 
            "other_name": "Humira"
        }, 
        "intervention_browse": {
            "mesh_term": "Adalimumab"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Crohn's Disease", 
            "Dose Escalation"
        ], 
        "lastchanged_date": "April 10, 2014", 
        "link": {
            "url": "http://www.rxabbvie.com"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Chikushino", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105698"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105698", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105700"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105700", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105717"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105717", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hamamatsu", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105699"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105699", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 107058"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 107058", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oita", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105718"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105718", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105697"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105697", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Otsu-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 118375"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 118375", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sakura", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105696"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105696", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Sapporo-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105695"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105695", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Suita-shi", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 105715"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 105715", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan"
                    }, 
                    "name": "Site Reference ID/Investigator# 107635"
                }, 
                "investigator": {
                    "last_name": "Site Reference ID/Investigator# 107635", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Multicenter Open-label Study of the Human Anti-Tumor Necrosis Factor (TNF) Monoclonal Antibody Adalimumab to Investigate Efficacy, Safety and Pharmacokinetics After Dose Escalation in Japanese Subjects With Crohn's Disease", 
        "other_outcome": [
            {
                "description": "Serum concentrations of adalimumab will be determined using a validated ligand binding assay (LBA) method under the supervision of the Bioanalysis Department of AbbVie.", 
                "measure": "Adalimumab serum concentrations", 
                "safety_issue": "No", 
                "time_frame": "Up to Week 52"
            }, 
            {
                "description": "AAA will be determined using a validated ligand binding assay (LBA) method under the supervision of the Bioanalysis Department of AbbVie.", 
                "measure": "Presence of anti-adalimumab antibody (AAA)", 
                "safety_issue": "No", 
                "time_frame": "up to Week 52"
            }
        ], 
        "overall_contact": {
            "email": "AbbVie_JPN_info_clingov@abbvie.com", 
            "last_name": "AbbVie  Japan Clinical Trials Registration Desk"
        }, 
        "overall_contact_backup": {
            "email": "debbie.tokimoto@abbvie.com", 
            "last_name": "Debbie  Tokimoto", 
            "phone": "847-938-9415"
        }, 
        "overall_official": {
            "affiliation": "AbbVie GK", 
            "last_name": "Morio  Ozawa, MS", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Clinical response will be determined by the Crohn's Disease Activity Index (CDAI) which is a research tool used to quantify the symptoms of patients with Crohn's disease.", 
            "measure": "Proportion of the subjects who achieved Clinical Response", 
            "safety_issue": "No", 
            "time_frame": "Week 8"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01958827"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Clinical remission is defined as CDAI < 150.", 
                "measure": "Proportion of the subjects who achieved clinical remission", 
                "safety_issue": "No", 
                "time_frame": "Every 4 weeks up to Week 52"
            }, 
            {
                "description": "C-reactive protein (CRP) is a protein found in the blood, the levels of which rise in response to inflammation.", 
                "measure": "Change in C-reactive protein (CRP)", 
                "safety_issue": "No", 
                "time_frame": "From Week 0 to Week 52"
            }, 
            {
                "description": "Hematology, Chemistry and Urinalysis", 
                "measure": "Change in Laboratory Test Variables", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 52"
            }, 
            {
                "description": "Blood pressure, heart rate, respiratory rate and body temperature", 
                "measure": "Change in Vital Sign Variables", 
                "safety_issue": "Yes", 
                "time_frame": "From Week 0 to Week 52"
            }, 
            {
                "measure": "Number of subjects with adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 70 days after Week 50"
            }
        ], 
        "source": "AbbVie", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "AbbVie", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}